Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study

European Journal of Medical Research

Volumn 16, Issue 2, 2011, Pages 67-70

  Cuevas Sánchez, Pedro ^a   Espinoza, W ^a   Perez C ^a   Angulo, J ^a   Gimenez Gallego G ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Actinic keratosis; Dobesilate; Fibroblast growth factor

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; POTASSIUM DOBESILATE; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; POTASSIUM DERIVATIVE;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; MALE; PRURITUS; TREATMENT OUTCOME; ADVERSE DRUG REACTION; CANCER GRADING; CLINICAL EVALUATION; CREAM; DRUG SAFETY; DRUG USE; OPEN STUDY; REMISSION; SIDE EFFECT; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BENZENESULFONATES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; SKIN NEOPLASMS; SUNLIGHT; TREATMENT OUTCOME;

EID: 79952791741     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Selasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000; 42: 4-7.
2. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol. 2003; 139: 1216-7. (Pubitemid 37128391)
3. Röwert-Huber J, Patel MJ, Forschner T et al.. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007; 156 (Suppl 3): 8-12. (Pubitemid 46632512)
4. Gupta AK. The management of actinic keratoses in the United States wih topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002; 70:30-6.
5. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004; 50: 714-21. (Pubitemid 38580548)
6. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2,5% hyaluronic gel. Br J Dermatol 2002; 146:194-200.
7. Campione E, Diluvio L, Paterno EJ, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1% gel. A preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010; 11: 45-50.
8. Cuevas P, Arrazola JM. Treatment of basal cell carcinoma with topical dobesilate. J Am Acad Dermatol. 2005; 53: 526-7. (Pubitemid 41195992)
9. Fernández IS, Cuevas P, Angulo J et al. Gentisic acid, a compound associated with plant defence and a metabolite of aspirin, heads a new class of in vivo FGF inhibitor. J Biol Chem. 2010; 285:11714-29.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-32.
11. Strieth S, Hartschuh W, Pilz L, Fusening NE. Angiogenic swith occurs late in squamous cell carcinomas of human skin. Br J Cancer. 2000; 82: 591-600. (Pubitemid 30085196)
12. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997; 8: 887-93. (Pubitemid 27353449)
13. Arbiser JL, Byers HR, Cohen C, Arbeits J. Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and immunohistochemistry. J Am Acad Dermatol. 2000; 42: 973-7. (Pubitemid 30368663)
14. Cuevas P, De Miguel R, Espinoza W et al. Antimelanoma effect of a synthetic inhibitor of fibroblast growth factor (FGF) [abstract no 79 plus Poster]. 13th World Congress on Cancers of the Skin; 2010 April 7-10. Madrid (Spain).